Advanced search
Start date
Betweenand
(Reference retrieved automatically from SciELO through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Haptoglobin study in myasthenia gravis

Full text
Author(s):
Leonardo H. Mendonça Oliveira [1] ; Marcondes C. França Jr [2] ; Anamarli Nucci [3] ; Denise Madureira de Oliveira [4] ; Elza Myiuki Kimura [5] ; Maria de Fátima Sonati [6]
Total Authors: 6
Affiliation:
[1] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
[2] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
[3] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
[4] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
[5] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
[6] Campinas State University. Faculty of Medical Sciences. Departments of Neurology - Brasil
Total Affiliations: 6
Document type: Journal article
Source: Arquivos de Neuro-Psiquiatria; v. 66, p. 229-233, 2008-06-00.
Abstract

OBJECTIVE: A cross-sectional study of haptoglobin (Hp) in myasthenia gravis (MG) was designed, with the objective to identify its values and correlate them with different disease status. METHOD: 46 patients were enrolled in the study, all having disease severity established according to the quantitative myasthenia gravis strength scores (QMGSS). Based on the functional scale determined by Myasthenia Gravis Foundation of America (MGFA) recommendations, patients were classified as having: complete stable remission (CSR; n=10); minimal manifestations-0 (MM0; n=6), minimal manifestations-1 (MM1; n=4); pharmacological remission (PR; n=6). Two other groups participated: thymomatous patients (T; n=10) and patients without imunosuppression or thymectomy, until the assessment for Hp (WIT; n=10). Hp dosage was done by immunonephelometry, blindly to clinical data. Student's t-test, Anova test and linear regression were employed for statistical analyses. RESULTS: Statistically significant differences occurred between CSR+MM0xWIT groups (86.62x157.57, p<0.001) and PR+MM1xWIT groups (73.93x157.57, p<0.001). Linear regression showed correlation between Hp levels and QMGSS (r=0.759, p<0.001). CONCLUSION: Our results suggest that Hp may be useful in clinical practice as a disease severity marker in MG. (AU)